68Ga-DOTA-TOC: Clinical Trials

3 trials of 68Ga-DOTA-TOC, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed, 1 recruiting, 1 terminated. 2 Early Phase 1, 1 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Early Phase 12Completed 1, Terminated 1
Phase 11Recruiting 1
Phase 21Recruiting 1

Follow 68Ga-DOTA-TOC: new trials by email Literature Review of 68Ga-DOTA-TOC trials Research Report on 68Ga-DOTA-TOC

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
61Cu-NODAGA-LM3 PET/CT for the Detection of Neuroendocrine Tumors (COPPER PET in NET)
61Cu-NODAGA-LM3, Comparator - Neuroendocrine Tumors
Phase 1 / Phase 2RecruitingUniversity Hospital, Basel, Switzerland272025-02-052025-05-30
Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumor
90Y-DOTA-TOC, 68Ga-DOTA-TOC - Neuroendocrine Tumor
Early Phase 1CompletedThomas Hope102017-07-012020-07-07
68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors
Computed Tomography, Gallium Ga 68-Edotreotide, Positron Emission Tomography - Meningioma, Metastatic Well Differentiated Neuroendocrine Neoplasm
Early Phase 1TerminatedM.D. Anderson Cancer Center42017-05-162021-02-15

Conditions studied

Neuroendocrine Tumors (3)  ·  Meningioma (1)  ·  Multiple Endocrine Neoplasia Type 1 (1)  ·  von Hippel-Lindau Disease (1)

Sponsors

M.D. Anderson Cancer Center (1)  ·  Thomas Hope (1)  ·  University Hospital, Basel, Switzerland (1)

Countries

United States (2)  ·  Switzerland (1)

Top investigators

Guillaume Nicolas, Dr. (1)  ·  Homer A Macapinlac, MD (1)  ·  Thomas Hope, MD (1)

NIH funding

2023 (1)